Orexo Dirección

Dirección controles de criterios 2/4

El CEO de Orexo's es Nikolaj Sorensen , nombrado en Feb 2013, tiene una permanencia de 11.33 años. compensación anual total es SEK6.12M, compuesta por 59.5% salario y 40.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.49% de las acciones de la empresa, por valor de SEK3.62M. La antigüedad media del equipo directivo y de la junta directiva es de 5.4 años y 4.2 años, respectivamente.

Información clave

Nikolaj Sorensen

Chief Executive Officer (CEO)

kr6.1m

Compensación total

Porcentaje del salario del CEO	59.5%
Permanencia del CEO	11.3yrs
Participación del CEO	0.5%
Permanencia media de la dirección	5.4yrs
Promedio de permanencia en la Junta Directiva	4.2yrs

Actualizaciones recientes de la dirección

Recent updates

Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 24% Below Its Share Price

Jun 14

Is Orexo (STO:ORX) A Risky Investment?

Apr 27

Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 92% Above Its Share Price

Oct 19

Would Orexo (STO:ORX) Be Better Off With Less Debt?

Sep 09

Are Investors Undervaluing Orexo AB (publ) (STO:ORX) By 47%?

May 26

Is Orexo (STO:ORX) Using Too Much Debt?

Apr 16

Orexo (STO:ORX) Has Debt But No Earnings; Should You Worry?

May 04

Increases to Orexo AB (publ)'s (STO:ORX) CEO Compensation Might Cool off for now

Apr 06

Orexo (STO:ORX) Share Prices Have Dropped 22% In The Last Five Years

Mar 16

Nikolaj Sørensen Is The President & CEO of Orexo AB (publ) (STO:ORX) And They Just Picked Up 2.1% More Shares

Feb 17

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Nikolaj Sorensen en comparación con los beneficios de Orexo?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-kr73m
Dec 31 2023	kr6m	kr4m	-kr128m
Sep 30 2023	n/a	n/a	-kr201m
Jun 30 2023	n/a	n/a	-kr195m
Mar 31 2023	n/a	n/a	-kr218m
Dec 31 2022	kr6m	kr4m	-kr178m
Sep 30 2022	n/a	n/a	-kr152m
Jun 30 2022	n/a	n/a	-kr177m
Mar 31 2022	n/a	n/a	-kr216m
Dec 31 2021	kr10m	kr4m	-kr223m
Sep 30 2021	n/a	n/a	-kr207m
Jun 30 2021	n/a	n/a	-kr240m
Mar 31 2021	n/a	n/a	-kr198m
Dec 31 2020	kr9m	kr3m	-kr84m
Sep 30 2020	n/a	n/a	kr4m
Jun 30 2020	n/a	n/a	kr201m
Mar 31 2020	n/a	n/a	kr288m
Dec 31 2019	kr6m	kr3m	kr219m
Sep 30 2019	n/a	n/a	kr232m
Jun 30 2019	n/a	n/a	kr182m
Mar 31 2019	n/a	n/a	kr178m
Dec 31 2018	kr5m	kr3m	kr138m
Sep 30 2018	n/a	n/a	kr113m
Jun 30 2018	n/a	n/a	kr79m
Mar 31 2018	n/a	n/a	kr32m
Dec 31 2017	kr6m	kr4m	kr23m

Compensación vs. Mercado: La compensación total de Nikolaj($USD586.28K) está por encima de la media de empresas de tamaño similar en el mercado Swedish ($USD257.80K).

Compensación vs. Ingresos: La compensación de Nikolaj ha aumentado mientras la empresa no es rentable.

CEO

Nikolaj Sorensen (52 yo)

11.3yrs

Permanencia

kr6,118,000

Compensación

Mr. Nikolaj Sørensen serves as Independent Director at Bioservo Technologies AB (publ) since May 6, 2019. He is Director at Gesynta Pharma AB. He has been the Chief Executive Officer of Orexo AB since Febr...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Nikolaj Sorensen	President & CEO	11.3yrs	kr6.12m	0.49% SEK 3.5m
Fredrik Jarrsten	Executive VP & CFO	1.8yrs	sin datos	0.076% SEK 550.0k
Cecilia Coupland	Senior VP & Head of Operations	5.4yrs	sin datos	0.042% SEK 302.2k
Lena Wange	Investor Relations & Communications Director	no data	sin datos	sin datos
Robert Ronn	Senior VP and Head of R&D	5.4yrs	sin datos	0.058% SEK 422.2k
Edward Kim	Chief Medical Officer	1.7yrs	sin datos	sin datos
Robert Deluca	President of Orexo US Inc	11.4yrs	sin datos	0.027% SEK 197.3k
Jesper Lind	Advisor	no data	sin datos	sin datos

5.4yrs

Permanencia media

54.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ORX es experimentado (5.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
George Wilkinson	Independent Director	5.2yrs	kr400.00k	0.056% SEK 403.2k
James Noble	Independent Chairman of the Board	4.2yrs	kr1.50m	0.19% SEK 1.4m
Staffan Lindstrand	Independent Director	22.4yrs	kr450.00k	0.099% SEK 717.0k
Christine Rankin	Independent Director	2.2yrs	kr550.00k	0.023% SEK 166.5k
Robin Evers	Independent Director	less than a year	kr50.00k	sin datos

4.2yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de ORX se considera experimentada (4.2 años de antigüedad promedio).

Orexo Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Independent Director recently bought kr94k worth of stock

Independent Director recently bought kr70k worth of stock

Orexo AB (Publ) Announces Board Resignations

President & CEO recently bought kr148k worth of stock

Independent Chairman of the Board recently bought kr361k worth of stock

Executive VP & CFO recently bought kr81k worth of stock

Recent updates

Independent Director recently bought kr94k worth of stock

Independent Director recently bought kr70k worth of stock

Orexo AB (publ) (STO:ORX) Soars 28% But It's A Story Of Risk Vs Reward

Orexo AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

Consensus EPS estimates upgraded to kr1.95 loss

First quarter 2024 earnings released: kr0.26 loss per share (vs kr1.86 loss in 1Q 2023)

Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US

Orexo AB (publ)'s (STO:ORX) Business And Shares Still Trailing The Industry

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 127%

Orexo AB (Publ) Announces Board Resignations

President & CEO recently bought kr148k worth of stock

New major risk - Financial position

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Orexo AB (publ) to Report Q4, 2024 Results on Feb 06, 2025

We Think Orexo (STO:ORX) Has A Fair Chunk Of Debt

Orexo AB (Publ) Announces FDA Acceptance of New Drug Application Filing for OX124

Orexo AB (Publ) Announces FDA Acceptance of New Drug Application Filing for OX124

Independent Chairman of the Board recently bought kr361k worth of stock

No longer forecast to breakeven

Executive VP & CFO recently bought kr81k worth of stock

Third quarter 2023 earnings: Revenues exceed analyst expectations

Orexo AB (publ) Announces Changes in the Board of Directors

Orexo AB (publ), Annual General Meeting, Apr 26, 2024

Orexo AB (publ) Announces Data from the MODIA Study Evaluating Impact on Use of Illicit Opioids

Orexo AB (Publ) Announces Henrik Kjær Hansen Will Resign from the Board of Directors

Orexo AB (publ) to Report Q2, 2024 Results on Jul 17, 2024

Orexo AB (publ.) Submits New Drug Application to FDA for OX124, a High-Dose Rescue Medication for Opioid Over Overio Overio Overio Overio

President & CEO recently bought kr74k worth of stock

Second quarter 2023 earnings: Revenues exceed analyst expectations

New minor risk - Profitability

Forecast breakeven date pushed back to 2025

Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 24% Below Its Share Price

Price target decreased by 15% to kr31.00

First quarter 2023 earnings: Revenues exceed analyst expectations

Is Orexo (STO:ORX) A Risky Investment?

President & CEO recently bought kr189k worth of stock

Orexo AB (publ) Submits New Drug Application to FDA for OX124, A High-Dose Rescue Medication for Opioid Overdose

Full year 2022 earnings released: kr5.17 loss per share (vs kr6.51 loss in FY 2021)

Orexo AB (publ.) Initiates Exploratory Feasibility Studies of amorphOX with Two Leading Biopharmaceutical and Vaccine Companies

Orexo AB (publ) to Report Fiscal Year 2022 Final Results on Mar 28, 2023

Consensus forecasts updated

Third quarter 2022 earnings released

Orexo AB (publ) Announces Last Patient Enrolled in Pivotal Study Evaluating the Efficacy of MODIA® in Combination with Sublingual Buprenorphine/ Naloxone for the Treatment of OUD

Orexo AB (publ) Appoints Edward Kim, M.D., as New Chief Medical Officer

Orexo AB (publ)'s (STO:ORX) Intrinsic Value Is Potentially 92% Above Its Share Price

Orexo AB (publ), Annual General Meeting, Apr 18, 2023

Orexo Announces Positive Data from Phase 1 Clinical Study for OX640

Orexo AB (publ) to Report Q1, 2023 Results on Apr 27, 2023

Would Orexo (STO:ORX) Be Better Off With Less Debt?

Consensus forecasts updated

Independent Director recently bought kr60k worth of stock

Second quarter 2022 earnings released

Orexo AB (Publ.) Announces Successfully Initiated the First Explorative Human Clinical Study for Ox640

Are Investors Undervaluing Orexo AB (publ) (STO:ORX) By 47%?

Consensus estimates of losses per share improve by 22%

First quarter 2022 earnings: Revenues in line with analyst expectations

Price target decreased to kr28.00

Orexo AB (publ) Announces Board Appointments

Is Orexo (STO:ORX) Using Too Much Debt?

Full year 2021 earnings: EPS exceeds analyst expectations

Director recently bought kr505k worth of stock

Consensus forecasts updated

Price target decreased to kr54.00

President & CEO recently bought kr243k worth of stock

Full year 2021 earnings: EPS exceeds analyst expectations

Orexo AB (publ) to Report Q4, 2022 Results on Jan 26, 2023

Orexo AB (Publ.) Develops Nasal Adrenaline Medication Based on the Novel Amorphox Platform

Orexo AB Provides Information About Its New Proprietary Drug Delivery Platform - Amorphox